Keywords: long-term, use, reminyl, beneficial, dementia, patients, who
Long-term use of Reminyl beneficial
Article | 15 November 2004
Dementia patients who receive more than 36 months' therapy with Shire Pharmaceuticals and Johnson & Johnson's Reminyl (galantamine) may be able to ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
